Neurol. praxi. 2023;24(2):116-120 | DOI: 10.36290/neu.2023.004

Migraine and hormonal contraception

MUDr. Ingrid Niedermayerová
Neurologie Brno, s. r. o., a II. neurologická klinika LF a FN Brno

The use of hormonal contraception (HC) has been increasing in recent decades. In women with migraine, the use of HC can significantly positively as well as negatively affect the course of the disease. In women with vascular risks, the use of inappropriate HC can make them more likely to develop ischaemic stroke. In migraine without aura, it is possible to prescribe both combined and gestagen-only HC; in migraine with aura, it is the gestagen-only type only. In menstrual migraine, in order to reduce menstruation-related migraine attacks, extended-cycle or continuous-cycle combined oral contraceptives (COCs), or gestagen-only HC can be administered. COCs are contraindicated in women with a risk of ischaemic stroke and in those with a history of ischaemic stroke. In women with risk factors of ischaemic stroke, but with no history of ischaemic stroke, it is possible to administer gestagen-only HC, with this type being relatively contraindicated after having ischaemic stroke.

Keywords: migraine, hormonal contraception, ischaemic stroke.

Received: December 19, 2022; Revised: December 19, 2022; Accepted: January 10, 2023; Prepublished online: January 10, 2023; Published: April 21, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Niedermayerová I. Migraine and hormonal contraception. Neurol. praxi. 2023;24(2):116-120. doi: 10.36290/neu.2023.004.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bouser MG, Conard J, Kittner S, et al. Recommendations on the risk of ischaemic stroke associated with use of combined oral contraceptives and hormone replacement therapy in women with migraine. Cephalalgia. 2000;20:155-156. Go to original source... Go to PubMed...
    2. De Leo V, Scolaro V, Musacchio MC, et al. Combined oral contraceptives in women with menstrual migraine without aura. Fertil Steril. 2011;96(4)917-920. Go to original source... Go to PubMed...
    3. European Contraception Policy Atlas, 2020. Available from: https://www.epfweb.org/node/89.
    4. Fait T. Antikoncepce. Maxdorf, Praha 2008: s.103.
    5. Hutchinson S, Peterlin BL. Menstrual Migraine. Oxford University Press, New York 2008: s. 95.
    6. Kolektiv autorů. Novinky v oblasti kombinované hormonální antikoncepce. Farmakoterapeutické informace. 2020;11:1-4.
    7. Kolektiv autorů. Novinky v oblasti kombinované hormonální antikoncepce. Farmakoterapeutické informace. 2020;12:1-2.
    8. Kolektiv autorů. Novinky v hormonální antikoncepci. Farmakoterapeutické informace. 2011;9:1-3.
    9. Křepelka P. Hormonální antikoncepce - zásady bezpečné praxe. 1. vyd. Praha: Mladá fronta, 2013. 284 s.: il., tab.; 24 cm. ISBN 978-80-204-2991-9.
    10. Lidegaard O, Kreiner S. Contraceptives and cerebral thrombosis: a five­‑year national case­‑control study. Contraception. 2002;65(3):197-205. Go to original source... Go to PubMed...
    11. Lidegaard Ø, Løkkegaard E, Jensen A, et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012;366(24):2257-66. Go to original source... Go to PubMed...
    12. Loder EW, Buse DC, Golub JR. Headache and combination estrogen­‑progestin oral contraceptive: Integrating evidence, guidelines, and clinical practice. Headache. 2005;45:224-231. Go to original source... Go to PubMed...
    13. MacGregor EA. Menstrual migraine:towards a definition. Cephalalgia. 1996;16:11-21. Go to original source... Go to PubMed...
    14. MacGregor A. Estrogen and migraine: correlations and prevention. Headache. 2008;48:S99-S107. Go to original source...
    15. Martin VT, Behbehani M. Ovarian hormons and migraine headache: Understanding mechanisms and pathogenesis - part 1. Headache. 2006;46:3-23. Go to original source... Go to PubMed...
    16. Martin VT, Behbehani M. Ovarian hormons and migraine headache: Understanding mechanisms and pathogenesis - part 2. Headache. 2006;46:365-386. Go to original source... Go to PubMed...
    17. Mastík J. Léčba menstruační a perimenstruační migrény. Neurol. praxi. 2008;(9)6:356-360.
    18. Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headaches in a general population. J Clin Epidemiol. 1991;44:1147-1157. Go to original source... Go to PubMed...
    19. Sacco S, Merki­‑Feld GS, Ægidius KL, et al. Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and the European Society of Contraception and Reproductive Health (ESCRH). J Headache Pain. 2017;18:108. https://doi.org/10.1186/s10194-017-0815-1. Go to original source... Go to PubMed...
    20. Sacco S, Merki­‑Feld GS, Ægidius KL, et al. Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and the European Society of Contraception and Reproductive Health (ESCRH). J Headache Pain. 2018;19:76. https://doi.org/10.1186/s10194-018-0896-5. Go to original source... Go to PubMed...
    21. Sannisto T, Kosunen E. Provision of contraception: a survey among primary care physicians in Finland. Acta Obstet Gynecol Scand. 2010;89(5):636-45. Go to original source... Go to PubMed...
    22. The International Classification of Headache Disorders. 3rd Edition, Cephalalgia. 2018;38(1):1-211. Go to original source...
    23. Unzeitig V, Čepický P, Dvořák V, et al. Doporučení k předpisu kombinované hormonální antikoncepce. Čes. Gynek. 2012;7(6):597-601.
    24. World Health Organization, Department of Reproductive Health and Research. Medical eligibility criteria for contraceptive use. WHO 2015. (Citace 23. 3. 2020). Available from: www.who.int/reproductive­‑health.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.